OMB No. 3117-0016/USITC No. 05-4-2276; Expiration Date: 6/30/05
(No response is required if currently valid OMB control number is not displayed)

FOREIGN PRODUCERS'/EXPORTERS' QUESTIONNAIRE

POLYCHLOROPRENE RUBBER FROM JAPAN

Return completed questionnaire to:

UNITED STATES INTERNATIONAL TRADE COMMISSION
Office of Investigations, Room 615
500 E Street, SW, Washington, DC 20436

So as to be received by the Commission by no later than March 3, 2005

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping review investigation concerning polychloroprene rubber from Japan (PCR) (inv. No. AA1921-129 (Second Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII.

Name of firm _____

Address _____

_____

World Wide Web address _____

Has your firm produced or exported PCR (as defined in the instruction booklet) since January 1, 1999?

☐ **NO** (Sign the certification below and promptly return only this page of the questionnaire to the Commission)

☐ **YES** (Read the instruction booklet carefully, complete all parts of the questionnaire, sign the certification, and return the entire questionnaire to the Commission)

CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By signing this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this review in any other import-injury investigations or reviews conducted by the Commission on the same or similar merchandise. (If you do not consent to such use, please note the certification accordingly.)

I acknowledge that information submitted in this questionnaire response and throughout this review may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this review or related proceedings for which this information is submitted, or in internal audits and investigations relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

_____ _____
Name and Title of Authorized Official ***Date***

_____ ( ) _____ ( ) _____
Signature of Authorized Official ***Phone*** ***Fax***

_____
E-mail address

PART I.--GENERAL QUESTIONS

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 20 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

_____ hours _____ dollars

I-1b. We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your response or send them to the above address.

I-2. Provide the name and address of establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

_____

_____

_____

I-3. Please provide the names and addresses of the **FIVE** largest U.S. importers of your firm's PCR in 2004.

_____

_____

_____

_____

_____

I-4. In Parts II and III of this questionnaire we request a copy of your company's most recent business plans. Does your company or any related firm have a business plan or any internal documents that describe, discuss, or analyze expected future market conditions for PCR?

☐ No ☐ Yes--Please provide the requested documents. If you are not providing the requested documents, please explain why not.

_____

_____

PART I.--GENERAL QUESTIONS--*Continued*

I-5. Does your firm or any related firm produce, have the capability to produce, or have any plans to produce PCR in the United States or other countries?

☐ No ☐ Yes--Please name the firm(s) and country(ies) below and, if U.S. producer(s), ensure that they complete the Commission's producer questionnaire (contact John Kitzmiller for copies of that questionnaire).

I-6. Does your firm or any related firm import or have any plans to import PCR into the United States?

☐ No ☐ Yes--Please name the firm(s) below and ensure that they complete the Commission's importer questionnaire (contact John Kitzmiller for copies of that questionnaire).

PART II.--TRADE AND RELATED INFORMATION

II-1. Has your firm experienced any plant openings, relocations, expansions, acquisitions, consolidations, closures, or prolonged shutdowns because of strikes or equipment failure; curtailment of production because of shortages of materials; or any other change in the character of your operations or organization relating to the production of PCR since December 6, 1973 (the date on which the antidumping finding under review became effective)?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-2. Does your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of PCR in the future?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue. **Include in your response a specific projection of your firm's capacity to produce PCR (in 1,000 pounds) for 2005 and 2006.**

II-3. Would your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

II-4. Does your firm have any plans to add, expand, curtail, or shut down production capacity and/or production of PCR in Japan in the future?

☐ No ☐ Yes--Please describe those plans, including planned dates and capacity/ production quantities involved, and the reason(s) for such change(s). If the plans are to add or expand capacity or production, list (in descending order of importance) the markets (countries) to which such additional capacity or production would be directed. Provide relevant portions of business plans or other supporting documentation that addresses this issue.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-5. Describe the production technology used in the production of PCR in Japan and identify major production inputs. Also discuss any significant changes in production technology since 1973 (the year the antidumping finding under review became effective).

_____

_____

_____

II-6. Has your firm since 1973 produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of PCR?

☐ No ☐ Yes--List the following information and report your firm's combined production capacity and production of these products and PCR in the periods indicated.

Product	Period	Basis for allocation of capacity data

(*Quantity* in 1,000 pounds)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
AVERAGE PRODUCTION CAPACITY						
PRODUCTION						

II-7. Has your firm since 1973 produced, or does your firm anticipate producing in the future, other products using the same production and related workers employed to produce PCR?

☐ No ☐ Yes--List the following information.

Product	Period	Basis for allocation of employment data

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-8. Please describe the constraint(s) that set the limit(s) on your production capacity.

_____

_____

II-9. What percentage of your firm's total sales in its most recent fiscal year was represented by sales of PCR?

_____ Percent

II-10. Is your firm able to switch production between PCR and other products in response to a relative price change in the price of PCR vis-a-vis the price of other products, using the same equipment and labor?

☐ No ☐ Yes--Please identify below the other products, the approximate time and cost involved in switching, and the minimum relative price change required for your firm to switch production to or from PCR.

_____

_____

II-11. Has your firm maintained any inventories of PCR in the United States (not including inventories held by firms identified in questions I-3, I-5, or I-6 above[1]) since 1999?

☐ No ☐ Yes--Report the quantity (in 1,000 pounds) of such **end-of-period** inventories below.

1999	**2000**	**2001**	**2002**	**2003**	**2004**

II-12. (a) Are your firm's exports of PCR subject to tariff or non-tariff barriers to trade (for example, antidumping or countervailing duty findings or remedies, tariffs, quotas, or regulatory barriers) in any countries other than the United States?

☐ No ☐ Yes--List the products(s), country(ies), the year each such barrier was imposed, and the type of barrier.

Product	**Country**	**Year imposed**	**Barrier (if tariff, give rate)**

[1] Such firms will report inventories in the Commission's importer or producer questionnaire.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

(b) Are your firm's exports of PCR subject to current investigations in any countries other than the United States that might result in tariff or non-tariff barriers to trade?

☐ No ☐ Yes--List the products(s), country(ies), and type of investigation.

Product	**Country**	**Type of investigation**

II-13. Identify export markets (other than the United States) that you have developed or where you have increased your sales of PCR as a result of the antidumping finding on PCR from Japan. Please identify and discuss below.

II-14. Describe the significance of the existing antidumping finding covering imports of PCR from Japan in terms of its effect on your firm's production capacity, production, home market shipments, exports to the United States and other markets, and inventories. You may wish to compare your firm's operations before and after the imposition of the order.

II-15. Would your firm anticipate any changes in its production capacity, production, home market shipments, exports to the United States and other markets, or inventories relating to the production of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, for any trends or projections you may provide.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-16. Please report production capacity, production, shipments, and inventories of PCR produced by your firm in Japan in **1999-2004**.

(*Quantity* in 1,000 pounds, *value* in 1,000 U.S. dollars)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
AVERAGE PRODUCTION CAPACITY[1] (*quantity*)						
BEGINNING-OF-PERIOD INVENTORIES[2] (*quantity*)						
PRODUCTION[3] (*quantity*)						
SHIPMENTS:						
Home market:						
Internal consumption/transfers (*quantity*)						
Commercial shipments: **_Quantity_**						
Value						
Exports to--						
United States:[4] **_Quantity_**						
Value						
All other export markets: **European Union:[5]** **_Quantity_**						
Value						
Asia:[6] **_Quantity_**						
Value						
Other:[7] **_Quantity_**						
Value						
Subtotal, all other export markets: **_Quantity_**						
Value						
Total exports (*quantity*)						
Total shipments (*quantity*)						
END-OF-PERIOD INVENTORIES (*quantity*)						

[1] The production capacity (see definitions in instructions booklet) reported is based on operating _____ hours per week, _____ weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported capacity (use additional pages as necessary).

_____

_____

[2] Reconciliation of data.--Please note that the quantities reported above should reconcile as follows: beginning-of-period inventories, plus production, less total shipments, equals end-of-period inventories. Do the data reported reconcile?

☐ Yes ☐ No--Please explain: _____

[3] Please estimate the percentage of total production of PCR in Japan accounted for by your firm's production in 2004:
_____ Percent

[4] Please estimate the percentage of total exports to the United States of PCR from Japan accounted for by your firm's exports in 2004:
_____ Percent

[5] Identify principal *European Union* export markets. _____

[6] Identify principal *Asian* export markets. _____

[7] Identify principal *other* export markets. _____

PART III.--MARKET FACTORS

III-1. Approximately what share of your firm's sales of PCR to U.S. customers in 2004 were on a (1) long-term contract basis (multiple deliveries for more than 12 months), (2) short-term contract basis (multiple deliveries up to 12 months), and (3) spot sales basis (for a single delivery)?

Type of sale	Share of sales (percent)
Long-term contracts	
Short-term contracts	
Spot sales	

III-2. If you sell on a long-term contract basis, please answer the following questions with respect to provisions of a typical long-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

III-3. If you sell on a short-term contract basis, please answer the following questions with respect to provisions of a typical short-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

III-4. What is the average lead time between a U.S. customer's order and the date of delivery for your firm's sales of PCR?

Source	Share of 2004 sales	Lead time
From inventory		
Produced to order		
Total	**100%**	

PART III.--MARKET FACTORS–*Continued*

III-5. To what extent have changes in the prices of raw materials affected your firm's selling prices for PCR during 1999-2004? Also discuss any anticipated changes in your raw material costs in the future, identifying the time period(s) involved and the factor(s) that you believe would be responsible for such changes. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-6. Have any changes occurred in any other factors affecting supply (e.g., changes in availability or prices of energy or labor; transportation conditions; production capacity and/or methods of production; technology; export markets; or alternative production opportunities) that affected the availability of Japan-produced PCR in the U.S. market since 1973?

☐ No ☐ Yes--Please note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.

III-7. (a) Do you anticipate any changes in terms of the availability of Japan-produced PCR in the U.S. market in the future?

☐ Increase ☐ No Change ☐ Decrease

(b) If you anticipate changes in supply, please identify the changes including the time period and the impact of such changes on shipment volumes and prices. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-8. Describe how easily your firm can shift its sales of PCR between the U.S. market and alternative country markets. In your discussion, please describe any contracts, other sales arrangements, or other constraints (including any third-country trade barriers such as tariffs, quotas, or other non-tariff barriers) that would prevent or retard your firm from shifting PCR between the U.S. and alternative country markets within a 12-month period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

PART III.--MARKET FACTORS–*Continued*

III-9. Is the product range, product mix, or marketing of PCR in your home market significantly different from the product range, product mix, or marketing of PCR for export to the United States or to third-country markets? Have there been any significant changes in the product range, product mix, or marketing of PCR in your home market, for export to the United States, or for export to third-country markets since 1973?

☐ No ☐ Yes--Please describe and quantify if possible.

III-10. Please discuss any anticipated changes in terms of the product range, product mix, or marketing of PCR in your home market, for export to the United States, or for export to third-country markets in the future, identifying the time period(s) involved and the factor(s) that you believe would be responsible for such changes. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-11. (a) Please list in order of importance any products that may be substituted for PCR.

(1) _____ (2) _____ (3) _____

(b) For each possible substitute product, please give examples of applications and end uses for which they are substitutes.

(c) Have changes in the prices of these products affected the price for PCR?

☐ No ☐ Yes–To what degree do changes in their prices affect the price for PCR? Does this effect have a time lag? If so, how long is the time lag for each substitute product? Does this vary by type of PCR or final end use?

PART III.--MARKET FACTORS–*Continued*

III-12. Have there been any changes in the number or types of products that can be substituted for PCR since 1973?

☐ No ☐ Yes--Please explain.

III-13. Do you anticipate any changes in terms of the substitutability of other products for PCR in the future?

☐ No ☐ Yes--Please describe. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

III-14. Is the PCR produced by your firm and sold in its home market interchangeable (i.e., can be used in the same applications) with your firm's PCR sold to the United States and/or to third-country markets?

☐ Yes ☐ No--Identify the market(s) and any differences in the products.

III-15. Describe the end uses of the PCR that you manufacture and sell to your home market. If these end uses differ from those of the PCR you sell to the U.S. market or to third-country markets, explain.

PART III.--MARKET FACTORS–*Continued*

III-16. Have there been any changes in the end uses of PCR since 1973?

☐ No ☐ Yes--Please describe.

_____

_____

III-17. Do you anticipate any changes in terms of the end uses of PCR in the future?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

_____

_____

III-18. How has demand within your home market and the United States (and outside the United States, if known) for PCR changed since 1973?

☐ Increased ☐ Unchanged ☐ Decreased

☐ Other (describe) _____

What were the principal factors affecting changes in demand?

_____

_____

III-19. Do you anticipate any future changes in PCR demand in your home market and the United States and, if known, the rest of the world?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

_____

_____

_____

_____

PART III.--MARKET FACTORS–*Continued*

III-20. Please compare market prices of PCR in your home market, the United States, and third-country markets, if known. Provide specific information as to time periods and regions for any price comparisons.

III-21. Describe briefly your home market for PCR, including the number of, and competition between, producers.

III-22. Do you face competition from imports of PCR in your home market?

☐ No ☐ Yes-- Please identify the country sources of any imports of PCR into your home market.

III-23. Please provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss PCR supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including Japan, and (3) the world as a whole. Of particular interest is such data from 1973 to the present and forecasts for the future.

III-24. Does your firm sell PCR over the internet?

☐ No ☐ Yes--Please describe, noting the estimated percentage of your firm's total sales of PCR in 2004 accounted for by internet sales.